EN|UA
Trick or Treatment

Evidence Files

Omega-3: The Heart Health Revolution That the 2018 Trials Quietly Complicated

For two decades, omega-3 fish oil was one of the most confidently recommended supplements in European pharmacies. Cardiologists endorsed it. Health authorities promoted it. Then three large independent trials published in 2018 showed that for most healthy people, fish oil capsules don't meaningfully reduce heart attacks, strokes, or cardiovascular death.

Verdict

TREATMENT (partially confirmed)

We searched PubMed and Cochrane Library for omega-3 evidence. The picture depends heavily on who is taking it and why. For high triglycerides: strong evidence, especially at prescription doses. For secondary prevention after a cardiac event: mixed and disputed. For primary prevention in healthy people: large modern RCTs show minimal benefit.

How the consensus formed — and cracked

The omega-3 story started with a 1970s study of Greenlandic Inuit who ate large amounts of fatty fish and had low rates of heart disease. The hypothesis: omega-3 fatty acids protect the cardiovascular system. Early trials seemed to confirm it. The GISSI-Prevenzione trial (1999, Italy) showed reduced cardiac death after heart attack. Enthusiasm was high.

Then came the scaling-up era — trials enrolling tens of thousands of participants with normal omega-3 levels. ASCEND (2018, 15,000 diabetics): minimal benefit on cardiovascular events, largely offset by increased bleeding risk. VITAL (2018, 25,000 healthy adults): no reduction in major cardiovascular events. ORIGIN (2012, 12,500 diabetics): zero difference versus placebo.

The effect that looked strong in early studies attenuated as research quality improved. This pattern — large effects in early trials, shrinking effects in larger, better-controlled trials — is a well-recognised sign of publication bias and early-trial overestimation.

Where the evidence actually stands

  • High triglycerides — strongest case: omega-3 (especially high-dose icosapentaenoic acid / EPA) meaningfully reduces triglycerides; prescription Vascepa (icosapentaenoic acid) showed cardiovascular benefit in REDUCE-IT trial
  • Secondary prevention (after heart attack) — disputed; some older positive trials, newer large RCTs mostly negative at over-the-counter doses
  • Primary prevention in healthy people — modern large RCTs: no significant reduction in cardiovascular events
  • Anti-inflammatory effects — real at the biochemical level; clinical translation to patient outcomes is inconsistent
  • Depression — small RCTs show modest signals; Cochrane: insufficient evidence to recommend for treatment of depression
  • Pregnancy — some evidence for DHA supporting fetal brain development; included in many prenatal recommendations

Over-the-counter fish oil vs. prescription omega-3

Standard supplement (1g/day, ~300mg EPA+DHA)

Sold for heart health, brain health, inflammation. The dose used in most large trials that showed null results. Probably doesn't meaningfully reduce cardiovascular risk in people without high triglycerides.

Prescription-dose EPA (4g/day, Vascepa)

Studied specifically in patients with high triglycerides already on statins. REDUCE-IT (2018): 25% relative risk reduction in cardiovascular events. This is a specific drug for a specific population — not general wellness supplementation.

Our Conclusion

Omega-3 is one of the most studied supplements in the world, and that's precisely why the answer is nuanced rather than simple. If you have high triglycerides and are on statins, there's a good evidence-based case for prescription-dose EPA — worth discussing with your cardiologist. If you're a generally healthy person taking fish oil capsules for heart protection, the large modern trials suggest you're probably not getting the benefit you're paying for. Eating two portions of fatty fish a week remains the most evidence-backed approach for most people.

Share:

This article is for informational purposes only and does not constitute medical advice. Trick or Treatment analyses the presence of clinical studies in open scientific databases — PubMed and Cochrane Library. The absence of studies in these databases does not automatically mean a drug is ineffective, but it does mean its effectiveness has not been confirmed by evidence-based medicine standards. Any treatment decisions should be made together with your doctor.